Literature DB >> 2504917

Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis.

R Segal1, D Caspi, M Tishler, I Wigler, M Yaron.   

Abstract

Sequential daily measurements of erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) were performed for one week after an I.V. injection of 7.5-13 mg methotrexate (MTX) in 18 patients with rheumatoid arthritis. Early decreases of ESR and CRP were observed. Serum CRP was more sensitive than ESR, displaying more pronounced falls from baseline to both the minimal and to the 7th day levels. Patients receiving their first dose of MTX (n = 9) exhibited a more prominent reduction of CRP levels in comparison to veteran MTX users (n = 9). The prompt response of acute phase reactants to MTX may correspond to the relatively rapid clinical effect of the drug in RA. It may also support an antiinflammatory mechanism of action of low dose MTX.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2504917

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

2.  Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.

Authors:  C H van Jaarsveld; J W Jacobs; M J van der Veen; A A Blaauw; A A Kruize; D M Hofman; H L Brus; G A van Albada-Kuipers; A H Heurkens; E J ter Borg; H C Haanen; C van Booma-Frankfort; Y Schenk; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 3.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 4.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 5.  Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent?

Authors:  S Tariq; S M Tariq
Journal:  Postgrad Med J       Date:  1993-10       Impact factor: 2.401

6.  Intra-articular steroids: confounder of clinical trials.

Authors:  H G Taylor; P D Fowler; M J David; P T Dawes
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

7.  Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders.

Authors:  T Ellingsen; N Hornung; B K Møller; J H Poulsen; K Stengaard-Pedersen
Journal:  Ann Rheum Dis       Date:  2006-08-11       Impact factor: 19.103

8.  Better effect of methotrexate on C-reactive protein during daily compared to weekly treatment in rheumatoid arthritis.

Authors:  P Seideman
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

9.  Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis.

Authors:  T C Wascher; J Hermann; H P Brezinschek; R Brezinschek; M Wilders-Truschnig; F Rainer; G J Krejs
Journal:  Clin Investig       Date:  1994-07

10.  Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis.

Authors:  A Nakajima; M Hakoda; H Yamanaka; N Kamatani; S Kashiwazaki
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.